Ovarian Cancer: Opportunity Analysis and Forecasts to 2028
- Pages: 162
- Published: September 2019
- Report Code: GDHC099POA
Ovarian cancer is a rare gynecological disease that spans a broad range of genetic and histological subtypes, for which platinum-based chemotherapy has been the standard of care (SOC) for decades. Ovarian cancer can be broken down into many different types of neoplasms based on specific histopathologic entities and clinical behaviors, and treatment depends on the specific tumor type.
Primary cytoreductive debulking surgery and platinum based chemotherapy form the SOC in advanced ovarian cancer. Roche’s angiogenesis inhibitor Avastin (bevacizumab) is optionally used with SOC doublet chemotherapy, particularly in patients with late stage disease. In addition to Avastin, three poly-ADP ribose polymerase (PARP) inhibitors, AstraZeneca’s Lynparza (olaparib), GSK’s Zejula (niraparib) and Clovis Oncology’s Rubraca (rucaparib), were recently introduced to market, and these four targeted therapies collectively began to transform the treatment paradigm for ovarian cancer.
The ovarian cancer market in the 7 major markets (7MM: US, France, Germany, Italy, Spain, UK, Japan) is expected to experience massive growth between 2018 and 2018. The main drivers of growth will be label expansions, which will broaden patient eligibility for branded agents, provide more therapeutic options for maintenance settings, and bring novel combinations of branded agents and pipeline agents into the treatment paradigm. GlobalData expects the launch of nine pipeline agents throughout the forecast period, which will further add to growth, including five checkpoint inhibitors, a small molecule inhibitor of vascular endothelial growth factor receptor (VEGF-R), a new PARP inhibitor, a folate receptor-targeting antibody drug conjugate, and a viral-based gene therapy prod.
Key Questions Answered
How will the use of PARP inhibitors throughout various lines of treatment affect the treatment algorithm?
The ovarian cancer market is characterized by a number of unmet needs. What are the main unmet needs in this market? Will the pipeline drugs under development fulfill these unmet needs?
Among nine late-stage pipeline agents entering the ovarian cancer market, which will make a significant impact? Which of these drugs will have the highest peak sales, and why?
Overview of ovarian cancer, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
Annualized ovarian cancer therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in three patient segments and 11 lines of therapy, forecast from 2018 to 2028.
Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the ovarian cancer therapeutics market.
Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for ovarian cancer. The most promising candidates in Phase III development are profiled.
Analysis of the current and future market competition in the global ovarian cancer market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Double-digit CAGR is expected in the ovarian cancer market from 2018 to 2028.
The main driver of the growth of the ovarian cancer market will be adoption of maintenance therapy across the 7MM, PARP inhibitor uptake in the first-line setting, launch of new pipeline agents, and increased screening rates for genetic markers.
Label expansions to broaden patient eligibility and the emergence of novel combinations of therapeutic agents will define the market over the forecast period.
Market growth will be stalled due to generic and biosimilar erosion, with some of the key products for ovarian cancer, Avastin and Lynparza, losing protection over the forecast period.
KOLs interviewed by GlobalData consider the binary categorization of ovarian cancer according to platinum-responsiveness outdated and highlight the need for more robust patient stratification according to genetic and histological biomarker status.
Reasons to buy
The report will enable you to:
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the global ovarian cancer market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global ovarian cancer market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Ovarian Cancer: Executive Summary
2.1 Double-Digit Growth Rate Expected for Ovarian Cancer Between 2018–2028
2.2 Drug Developers Expand Labels Through Novel Combinations and Broadening of Patient Eligibility
2.3 Unmet Need for More Effective Therapies in the Treatment-Resistant Disease Setting Will Largely Remain Unaddressed
2.4 An Individualized Treatment Paradigm Emerges for the First-Line Setting, While Targeted Therapies Are Struggling to Deliver for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
2.5 What Do Physicians Think?
3.2 Related Reports
3.3 Upcoming Related Reports
4 Disease Overview
4.1 Etiology and Pathophysiology
4.2 Classification or Staging Systems
5.1 Disease Background
5.2 Risk Factors
5.3 Global and Historical Trends
5.3.1 7MM Trends in Diagnosed Incidence
5.3.2 7MM Trends in Observed Survival
5.4 Forecast Methodology
5.4.2 Forecast Assumptions and Methods
5.5 Epidemiological Forecast for Ovarian Cancer (2018–2028)
5.5.1 Diagnosed Incident Cases of Ovarian Cancer
5.5.2 Age-Specific Diagnosed Incidence of Ovarian Cancer
5.5.3 Five-Year Diagnosed Prevalent Cases of Ovarian Cancer
5.5.4 Diagnosed Incident Cases of Ovarian Cancer by Stage at Diagnosis
5.5.5 Diagnosed Incident Cases of Cancer of the Ovary (C56) by Histologic Subtype
5.5.6 Diagnosed Incident Cases of Ovarian Cancer with an Associated Germline BRCA Mutation
5.5.7 Diagnosed Incident Cases of Ovarian Cancer with an Associated Somatic BRCA Mutation
5.5.8 Diagnosed Incident Cases of Ovarian Cancer with HRD
5.5.9 Diagnosed Incident Cases of EOC with FRα Overexpression
5.6.1 Epidemiological Forecast Insight
5.6.2 Limitations of Analysis
5.6.3 Strengths of Analysis
6 Current Treatment Options
7 Unmet Needs and Opportunity Assessment
7.2 Improved Front-Line Therapies
7.3 Alternative Treatment Options for Platinum-Refractory/Resistant Patients
7.4 Individualized Treatment Approaches
7.5 Therapy Option for Histological Subtypes Beyond High-Grade Serous Ovarian Cancer
7.6 An Early-Stage Diagnostic for Ovarian Cancer
8 R&D Strategies
8.1.1 PARP Inhibitors Are Becoming a Focus of Clinical Development
8.1.2 Development of Companion Diagnostic and Robust Biomarker Platforms
8.1.3 Novel Mechanism of Action: Folate Receptor Alpha Targeting
8.1.4 Cell-Based Therapies at the Early Stages of Clinical Development
8.1.5 Platinum-Refractory Disease: Patients Might Have to Wait for Breakthrough Therapies
8.2 Clinical Trial Design
8.2.1 Current Clinical Trial Endpoints
8.2.2 Future Clinical Trial Endpoints
8.2.3 Moving Beyond the Current Platinum-Sensitive/Resistant Paradigm for Patient Recruitment in Clinical Trials
9 Pipeline Assessment
9.2 Innovative Early-Stage Approaches
9.3 Other Drugs in Development
10 Pipeline Valuation Analysis
10.1 Clinical Benchmark of Key Pipeline Drugs
10.2 Commercial Benchmark of Key Pipeline Drugs
10.3 Competitive Assessment
10.4 Top-Line 10-Year Forecast
11.3.1 Forecasting Methodology
11.3.2 Diagnosed Patients
11.3.3 Percent Drug-Treated Patients
11.3.4 Drugs Included in Each Therapeutic Class
11.3.5 Launch and Patent Expiry Dates
11.3.6 General Pricing Assumptions
11.3.7 Individual Drug Assumptions
11.3.8 Generic Erosion
11.3.9 Pricing of Pipeline Agents
11.4 Primary Research – KOLs Interviewed for This Report
11.5 Primary Research – Prescriber Survey
11.6 About the Authors
11.6.2 Therapy Area Directors
11.6.4 Managing Epidemiologist
11.6.5 Global Director of Therapy Analysis and Epidemiology
11.6.6 Global Head and EVP of Healthcare Operations and Strategy
11.7 About GlobalData
11.8 Contact Us
List of Tables
Table 1: Ovarian Cancer: Key Metrics in the 7MM
Table 2: FIGO Guidelines: Staging Classification for Cancer of the Ovary, Fallopian Tube, and Peritoneum
Table 3: Risk Factors for Ovarian Cancer
Table 4: Treatment Guidelines for Ovarian Cancer, 2019
Table 5: Leading Treatments for Ovarian Cancer, 2019
Table 6: Potential Classification Systems for Recurrent Ovarian Cancer
Table 7: Comparison of Therapeutic Classes in Development for Ovarian Cancer, 2018–2028
Table 8: Innovative Early-Stage Approaches for Ovarian Cancer, 2019
Table 9: Other Drugs in Development for Ovarian Cancer, 2019
Table 10: Clinical Benchmark of Key Pipeline Immuno-oncology Drugs – Ovarian Cancer
Table 11: Clinical Benchmark of Key Pipeline Targeted Therapy Drugs – Ovarian Cancer
Table 12: Commercial Benchmark of Key Pipeline Immuno-oncology Drugs – Ovarian Cancer
Table 13: Commercial Benchmark of Key Pipeline Targeted Therapy Drugs – Ovarian Cancer
Table 14: Key Events Impacting Sales for Ovarian Cancer, 2018–2028
Table 15: Ovarian Cancer Market – Global Drivers and Barriers, 2018–2028
Table 16: Ovarian Cancer US Market – Drivers and Barriers, 2018–2028
Table 17: Ovarian Cancer 5EU Market – Drivers and Barriers, 2018–2028
Table 18: Ovarian Cancer Japan Market – Drivers and Barriers, 2018–2028
Table 19: Key Historical and Projected Launch Dates for Ovarian Cancer
Table 20: Key Historical and Projected Patent Expiry Dates for Ovarian Cancer
Table 21: Average Body BSA Across the 7MM
Table 22: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
List of Figures
Figure 1: Global Sales Forecast by Country for Ovarian Cancer in 2018 and 2028
Figure 2: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, Avastin in Combination with Paclitaxel + Carboplatin
Figure 3: Diagnosed Incidence of Ovarian Cancer, 7MM, Women, Ages ≥18 Years, 2008–2028, Cases per 100,000 Population
Figure 4: Sources Used and Not Used for Diagnosed Incident Cases of Ovarian Cancer
Figure 5: Sources Used for Diagnosed Incident Cases of Ovarian Cancer by Stage at Diagnosis
Figure 6: Sources Used for Diagnosed Incident Cases of Cancer of the Ovary (C56) by Histologic Subtype
Figure 7: Sources Used for Diagnosed Incident Cases of Ovarian Cancer with an Associated Germline BRCA Mutation
Figure 8: Sources Used for Diagnosed Incident Cases of Ovarian Cancer with an Associated Somatic BRCA Mutation
Figure 9: Sources Used for Diagnosed Incident Cases of Ovarian Cancer with HRD
Figure 10: Sources Used for EOC Cases with FRα Overexpression
Figure 11: Diagnosed Incident Cases of Ovarian Cancer, 7MM, Women, Ages ≥18 Years, 2018
Figure 12: Age-Specific Diagnosed Incident Cases of Ovarian Cancer, 7MM, Women, Ages ≥18 Years, 2018
Figure 13: Five-Year Diagnosed Prevalent Cases of Ovarian Cancer, 7MM, Women, Ages ≥18 Years, 2018, N
Figure 14: Diagnosed Incident Cases of Ovarian Cancer by Stage at Diagnosis, 7MM, Women, Ages ≥18 Years, 2018, N
Figure 15: Diagnosed Incident Cases of Cancer of the Ovary (C56) by Histologic Subtype, 7MM, Women, Ages ≥18 Years, 2018, N
Figure 16: Diagnosed Incident Cases of Ovarian Cancer with an Associated Germline BRCA Mutation, 7MM, Women, Ages ≥18 Years, 2018, N
Figure 17: Diagnosed Incident Cases of Ovarian Cancer with an Associated Somatic BRCA Mutation, 7MM, Women, Ages ≥18 Years, 2018, N
Figure 18: Diagnosed Incident Cases of Ovarian Cancer with HRD, 7MM, Women, Ages ≥18 Years, 2018, N
Figure 19: Diagnosed Incident Cases of EOC with FRα Overexpression, 7MM, Women, Ages ≥18 Years, 2018, N
Figure 20: Top-Level Treatment Flow Chart for Ovarian Cancer Patients
Figure 21: Unmet Needs and Opportunities in Ovarian Cancer
Figure 22: Overview of the Development Pipeline in Ovarian Cancer
Figure 23: Key Phase II/III Trials for IO Agents in Ovarian Cancer Pipeline in the 7MM, 2019
Figure 24: Key Phase II/III Trials for Targeted Therapy Agents in Ovarian Cancer Pipeline in the 7MM, 2019
Figure 25: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, Avastin + Chemotherapy
Figure 26: Global (7MM) Sales Forecast by Country for Ovarian Cancer in 2018 and 2028
Figure 27: Global Sales Forecast by Class for Ovarian Cancer in 2018 and 2028
Figure 28: Sales Forecast by Class for Ovarian Cancer in the US in 2018 and 2028
Figure 29: Sales Forecast by Class for Ovarian Cancer in the 5EU in 2018 and 2028
Figure 30: Sales Forecast by Class for Ovarian Cancer in Japan in 2018 and 2028